title: Efficacy evaluation of live Escherichia coli expression Brucella P39 protein combined with CpG oligodeoxynucleotides vaccine against Brucella melitensis 16M, in BALB/c mice.
abstract: Brucella is gram-negative bacteria responsible for brucellosis in a wide variety of animals and humans. BALB/c mice were immunized with live Escherichia coli expression the p39 gene of Brucella melitensis, a gene coding for the periplasmic binding protein. Mice were injected with either E. coli BL21 (DE3) pEt15b or E. coli BL21 (DE3) pEt15b-p39 alone or adjuvanted with either CpG oligodeoxynucleotides (CpG ODN) or non-CpG ODN. E. coli BL21 (DE3) pEt15b-p39 with CpG ODN or with non-CpG ODN mice groups showed a significant IFN-γ production and T-cell proliferation as a reaction to P39 antigen. In addition, antibody responses (IgG, IgG1 and IgG2a), were only found in these two mice groups. A higher level of protection against B. melitensis 16M were observed in mice immunized with E. coli BL21 (DE3) pEt15b-p39 and CpG ODN comparing with those immunized with E. coli BL21 (DE3) pEt15b-p39 alone or with non-CpG ODN. No protection against B. melitensis 16M was observed in mice immunized with E. coli BL21 (DE3) pEt15b alone or with the adjuvant. Rev.1 protection at 4 and 8 weeks post-challenge was more effective than that observed with E. coli BL21 (DE3) pEt15b-p39 and CpG ODN.
authors.affiliation: Department of Molecular Biology and Biotechnology, Atomic Energy Commission, P.O. Box 6091, Damascus, Syria. ascientific@aec.org.sy
authors.forename: Ayman
authors.initials: A
authors.lastname: Al-Mariri
authors.forename: Nermeen Haj
authors.initials: NH
authors.lastname: Mahmoud
authors.forename: Razan
authors.initials: R
authors.lastname: Hammoud
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000235:genetics; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D002004:Brucella Vaccine / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D017347:Brucella melitensis / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D002006:Brucellosis / Q000276:immunology / Q000517:prevention & control; D018899:CpG Islands / Q000235:genetics; D004926:Escherichia coli / Q000235:genetics / Q000276:immunology; D005260:Female; D007111:Immunity, Cellular; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage* / Q000276:immunology; D033902:Periplasmic Binding Proteins / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D013997:Time Factors
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D002004:Brucella Vaccine; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides; D033902:Periplasmic Binding Proteins; D011994:Recombinant Proteins; C119927:p39 protein, Brucella